Loading
companiesCompany
Insilico Medicine
Generative-AI drug discovery company, listed in Hong Kong in December 2025, with a pan-KRAS candidate and a pan-TEAD inhibitor in the clinic.
Overview
Insilico's 2025 listing was the largest Hong Kong biotech IPO of the year (HKD 2.28B). Pipeline of 31 nominated candidates with 13 IND clearances; oncology assets include ISM6166 (pan-KRAS) and ISM6331 (pan-TEAD, phase 1 data at ESMO 2026 in mesothelioma and solid tumours). Profitable in H1 2026 on licensing revenue.
Similar pages
- CompanyIsomorphic Labs
Shares De novo designed protein binders, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- CompanyRecursion Pharmaceuticals
Shares A virtual cancer cell that predicts what a drug will do before you test it, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- CompanyGenerate:Biomedicines
Shares De novo designed protein binders, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI-driven drug & target discovery, The valley of death between lab and product.
- TechnologyPhenom-2 and Recursion OS
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- TechnologyBoltz-1 / Boltz-2 (MIT, open)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- TechnologyChai-1 / Chai-2
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- CompanyCradle
Shares De novo designed protein binders, AI-driven drug & target discovery.
- CompanyLatent Labs
Shares De novo designed protein binders, AI-driven drug & target discovery.